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The accelerated pace of gene discovery and molecular medicine portend a future in which
information about a plethora of disease genes can be readily obtained. As at-risk populations are
identified, research can be done to determine effective prevention and treatment strategies that will
lower the personal, social and perhaps the financial costs of disease in the future. We all carry genes
that predispose to common illnesses. In many circumstances knowing this information can be
beneficial, as it allows individualized strategies to be designed to reduce the risk of illness. But, as
knowledge about the genetic basis of common disorders grows, so does the potential for discrimination
in health insurance coverage for an ever increasing number of Americans.
The use of genetic information to exclude high-risk people from health care by denying coverage
or charging prohibitive rates will limit or nullify the anticipated benefits of genetic research. In addition
to the real and potentially devastating consequences of being denied health insurance, the fear of
discrimination had other undesirable effects. People may be unwilling to participate in research and to
share information about their genetic status with their health care providers or family members because
of concern about misuse of this information. As genetic research progresses and preventive and
treatment strategies are developed, it will be increasingly important that discrimination and the fear of
discrimination not be a roadblock to reaping the benefits. To address these issues, the National Institute
of Health-Department of Energy (NIH-DOE) Working Group on Ethical, Legal, and Social Implications
(ELSI) of the Human Genome Project and the national Action Plan on Breast Cancer have jointly
developed a series of recommendations for state and federal policymakers which are presented below.
In the past, genetic information has been used by insurers to discriminate against people. In the
early 1970s, some insurance companies denied coverage and charged higher rates to African Americans
who were carriers of the gene for sickle cell anemia (1). Contemporary studies have documented cases
of genetic discrimination against people who are healthy themselves but who have a gene that
predisposes them or their children to a later illness such as Huntington’s disease (2). In a recent survey
of people with a known genetic condition in the family, 22% indicated that they had been refused health
insurance coverage because of their genetic status, whether they were sick or not (3).
As a case example, Paul (not his real name) is a healthy, active 4-year-old, but he has been twice
denied health insurance. Paul’s mother died in her sleep of sudden cardiac arrest when Paul was only 5
months old. Paul’s maternal uncle also died of sudden cardiac arrest when he was in his twenties. After
these sudden and unexpected deaths, Paul’s family began to hunt to discover the cause. Their search
finally led to a research geneticist who was able to determine that several family members, including
Paul and his mother, carried an alteration in a gene on chromosome 7. This gene is one of several genes
that cause the long QT syndrome, so-called because of the distinctive diagnostic pattern on an
electrocardiogram.

Several years ago, Paul’s father, Bob, lost his job and with it the group policy that provided
health insurance coverage for Paul and him. Paul’s father has repeatedly applied for a family health
insurance policy with a major insurance company. The company agreed to cover Bob but refused to
issue a family policy that would cover Paul because he has inherited the altered gene for the long QT
syndrome from his mother.
The story of Jackie and Emma further illustrates the social, ethical, and legal dilemmas
presented by the revelation of genetic information. Sisters Jackie and Emma, along with many other
members of their family, have been tested as part of a research protocol for alterations in the gene
BRCA1 that confers hereditary susceptibility to breast and ovarian cancer. Both were offered an
opportunity to learn the results of their genetic tests and both accepted. They each learned they carry
an altered form of the gene, putting them at increased risk for breast and ovarian cancer.
After finding out the results of her genetic test, Emma had a mammogram that showed a very
small lesion in her breast. A subsequent biopsy revealed carcinoma, and Emma decided to proceed with
a bilateral mastectomy because of the substantial risk of cancer arising in the opposite breast. Her
lymph nodes were negative for cancer, so her prognosis for cure is very good.
Emma’s sister Jackie also tested positive for the same alteration in the BRCA1 gene, though no
cancer was detected. Although the benefit of prophylactic mastectomy in reducing the risk for breast
cancer is not yet known, she decided to have a bilateral prophylactic mastectomy. Emma and Jackie feel
strongly that they have benefited from knowing this genetic information but are fearful that it will be
used against them and their family by insurers and employers. They both keep their genetic status
secret and are so fearful of losing their health insurance that they used assumed names when sharing
their story at a recent workshop on genetic discrimination (4).
Emma and Jackie’s story is not unique. An estimated 1 in 500 women carry a mutation in the
BRCA1 gene that may confer as much at an 85% chance of breast cancer and a 50% chance of ovarian
cancer (5). Although substantial uncertainty exists about the relative value of the available options
(surgery compared with intensive surveillance) for a woman with a BRCA1 mutation, it is likely that
ultimately this information will be medically useful.
Health Insurance in the United States
Because of high costs, insurance is essentially required to have access to health care in the
United States. Over 40 million people in the United States are uninsured (6). Group insurance,
individual insurance, self-insurance and publicly financed insurance (for example, Medicare and
Medicaid) are the principal forms of health insurance in the United States for the 240 million Americans
with coverage. Most people get their health insurance through their employer. Many employers
provide health insurance coverage though self-funded plans in which the employer, either directly or
through a third party, provides health insurance coverage. For individuals and small groups, insurance
providers use medical history as well as individual risk factors, such as smoking, to determine whether to
provide coverage and under what terms. This is known as underwriting. Insurers argue that
underwriting is essentially in a voluntary market to prevent “adverse selection,” in which individuals
elect not to purchase insurance until they are already ill or anticipate a future need for health care.
Insurers fear that individuals will remain uninsured until, for example, they receive a genetic test result
indicating a predisposition to some disease such as breast or colon cancer.

In the absence of the ability to detect hereditary susceptibility to disease, the costs of medical
treatment have been absorbed under the current health insurance system of shared risk and shared
cost. Today, our understanding of the relation between a misspelling in a gene and future health is still
incomplete, thus limiting the ability of insurers to incorporate genetic risks into actuarial calculations of
a large scale. As genetic research enhances the ability to predict individuals’ future risk of diseases,
many Americans may become uninsurable on the basis of genetic information.
State and Federal Initiatives
A recent survey has shown that a number of states have enacted laws to protect individuals
from being denied health insurance on the basis of genetic information (7). The first laws addressing
genetic discrimination were quite limited in scope and focused exclusively on discrimination against
people with a single genetic trait (8). Since the Human Genome Project was launched in the 1990, eight
states have enacted some form of protection against genetic discrimination in health insurance. The
recently enacted state laws are not limited to a specific genetic trait but apply potentially to an
unlimited number of genetic conditions. These state laws prohibit insurers from denying coverage on
the basis of genetic test results, and prohibit the use of this information to establish premiums, charge
differential rates, or limit benefits. A few of these states, including Oregon and California, integrate
protection against discrimination in insurance practices with privacy protections that prohibit insurers
from requesting genetic information and from disclosing genetic information without authorization.
Two factors limit the protection against discrimination afforded by current state laws. First, the
federal Employee Retirement Income Security Act exempts self funded plans from state insurance laws.
Nationwide, over one-third of the nonelderly insured population obtains health insurance coverage
through a self-funded plan. Second, nearly all of the state laws focus narrowly on genetic tests, rather
than more broadly on genetic information generated by family history (7). Limiting the scope of
protection to results of genetic tests means that insurers are only prohibited from using the results of a
chemical test of DNA, or in some cases, the protein product of a gene. But insurers can use other
phenotypic indicators, patterns of inheritance of genetic testing as the basis of discrimination.
Meaningful protection against genetic discrimination required that insurers be prohibited from using all
information about genes, gene products, or inherited characteristics to deny or limit health insurance
coverage.
No federal laws are currently in place to prohibit genetic discrimination in health insurance (9).
The Clinton Administration’s proposal to reform the health care system and provide health insurance for
all Americans did prohibit limiting access or coverage on the basis of “existing medical conditions or
genetic predisposition to medical conditions” (10). Congressional efforts to reform the health care
system in 1995 have been much more modest and are targeted at guaranteeing access, portability, and
renewability of coverage and at leveling the playing field in the insurance market so that the same rules
apply to insured and self-funded plans. Recent federal health insurance reform proposals attempt to
guarantee the availability of health care by prohibiting insurers from denying coverage on the basis of
health status, medical condition, claims experience, or medical history of a participant. Most of the
proposals permit exclusions for pre-existing conditions, but these are time limited.
It is not clear if the current health insurance reform proposals would prohibit insurers from
denying coverage on the basis of genetic information. Genetic information is distinct from other types
of medical information because it provides information about an individual’s predisposition to future
disease. In addition, genetic information can provide clues to the future health risks for an individual’s

family members. If enacted, current health reform proposals would prohibit denying insurance to those
currently suffering from disease or with a past history of disease. But these proposals may not protect
people like Paul, who are healthy but have a genetic predisposition to disease, from being refused
insurance coverage. Currently proposals also may fail to protect couples who, although healthy
themselves, carry the gene for a recessive disorder such as cystic fibrosis that might affect their children
or future children.
Recommendations
Planners of the Human Genome Project recognized from the beginning that maximizing the
medical benefits of genome research would require a social environment in which health care
consumers were protected from discrimination and stigmatization based on their genetic make-up.
Genome programs at both the DOE and the National Center for Human Genome Research, a component
of NIH, have each set aside a portion of their research budget to anticipate, analyze, and address the
ELDI of new advances in human genetics. The original planners also created the NIH-DOE ELSI Working
Group, which has a broad and diverse membership including genome scientist; medical geneticists;
experts in law, ethics, and philosophy; and consumers, to explore and propose options for the
development of sound professional and public policies related to human genome research and its
applications. The ELSI Working Group has long been involved in discussions about the fair use of genetic
information. In a 1993 report, “Genetic Information and Health Insurance” (11), the ELSI Working Group
recommended a return to the risk-spreading goal of insurance. The Working Group suggested that
individuals be given access to health care insurance irrespective of information, including genetic
information about their past, current, or future health status. Because denial of insurance coverage for
a costly disease such as breast cancer may prove to be a death sentence for many women, the National
Action Plan on Breast Cancer (NAPBC), a public-private partnership designed to eradicate breast cancer
as a threat to the lives of American women, has indentified genetic discrimination in health insurance as
a high priority (12).
Building on their shared concerns, the NAPBC (13) and the ELSI Working Group (14) recently
cosponsored a workshop on genetic discrimination and health insurance (4). Scientists, representatives
from the insurance industry, and members of the ELSI Working Group and the NAPBC participated in the
1-day session. On the basis of the information presented at the workshop, the ELSI Working Group and
the NAPBC developed the following recommendations and definitions for state and federal
policymakers to protect against genetic discrimination.
1. Insurance providers should be prohibited from using the genetic information, or an
individual’s request for genetic services to deny or limit any coverage or establish eligibility,
continuation, enrollment, or contribution requirements.
2. Insurance providers should be prohibited from establishing differential rates or premium
payments based on genetic information or an individual’s request for genetic services.
3. Insurance providers should be prohibited from requesting or requiring collection or
disclosure of genetic information.
4. Insurance providers and other holders of genetic information should be prohibited from
releasing genetic information without prior written authorization of the individual. Written
authorization should be required for each disclosure and include to whom the disclosure
would be made. The definitions are as follows.
Genetic information is information about genes, gene products, or inherited characteristics
that may derive from the individual or a family member. Insurance provider means an insurance

company, employer, or any other entity providing a plan of health insurance or health benefits
including group or individual health plans whether fully insured or self-funded.
These recommendations have been endorsed by the National Advisory Council for
Human Genome Research (NACHGR) (15). The NACHGR stresses the positive value of genetic
information for improving the medical care of individual patients and the need to ensure the
freedom of patients and their health care providers to use genetic information for patient care.
The NACHGR views the elimination of the use of genetic information to discriminate against
individuals in their access to health insurance as a critical step toward these goals.
The ability to obtain sensitive genetic information about individuals, families, and even
populations raises profound and troubling questions about who will have access to this
information and how it will be used. The recommendations presented here for state and
federal policy-makers are intended to help ensure that our current social, economic, and health
care policies keep pace with both the opportunities and challenges that the new genetics
present for understanding the causes of disease and developing new treatment and preventive
strategies.
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